Research programme: TRPV cation channel inhibitors - Purdue PharmaAlternative Names: BCTC; Research programme: vanilloid receptor 1 antagonists - Purdue Pharma
Latest Information Update: 21 Jul 2010
At a glance
- Originator Purdue Pharma
- Class Piperazines
- Mechanism of Action TRPV cation channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 21 Jul 2010 Discontinued - Preclinical for Pain in USA (unspecified route)
- 23 Sep 2003 Preclinical trials in Pain in USA (unspecified route)